The cluster is dominated by option-exercise-related sales, which are routine and non-informational. The only pure open-market sale (Director Norwalk, $210K) is too small to signal a bearish view. No actionable trading signal here, monitor for any upcoming earnings or pipeline catalysts that could drive the stock.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 9 $165.24entry
- T+1 · 5mo ago −2.65%α −1.07% · $160.86
- T+5 · 5mo ago −3.47%α −5.88% · $159.51
- T+20 · 4mo ago +7.41%α +5.97% · $177.49
- T+60 · 3mo ago −4.51%α −8.32% · $157.79
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A cluster of insider selling at Neurocrine Biosciences, totaling ~$4.5M over a week, is dominated by C-suite officers exercising options and selling shares. While the dollar value is modest relative to the $16.5B market cap (~0.03%), the concentration of senior executives (CMO, CHRO, CSO, CRO) selling at similar times warrants attention, though the sales are largely tied to option exercises and tax withholding, reducing their informational signal.
Key Financial Metrics
Key Facts
- Four insiders sold shares totaling ~$4.53M in a 7-day window (May 29–June 4, 2026).
- Sales include C-suite: Chief Medical Officer, Chief Human Resources Officer, Chief Scientific Officer, and Chief Regulatory Officer.
- Total sales represent ~0.03% of NBIX's $16.5B market cap, well below the 0.1% materiality threshold.
- Most sales were preceded by option exercises (non-cash) or tied to tax withholding, suggesting liquidity-driven rather than informational selling.
- Director Norwalk Leslie V sold $210K in a standalone open-market sale, the only pure open-market sell in the cluster.
Financial Impact
Total insider sales of ~$4.53M, or ~0.03% of market cap, immaterial in absolute and relative terms.
Risk Factors
- Continued insider selling could erode confidence if it accelerates in future windows.
- No material risk identified from this cluster alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NBIX-1780956502789 |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers